American Tower

uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025.» Mehr auf seekingalpha.com

Evaluate the expected performance of American Tower (AMT) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.» Mehr auf zacks.com

I created a diversified REIT portfolio for my mom, aiming for consistent income and optimized total returns, with an average dividend yield of 4.9%. Key REITs include Invitation Homes, Apple Hospitality, Realty Income, Healthpeak, Mid-America, Sun Communities, American Tower, VICI Properties, Prologis, and Ladder Capital. Each REIT was selected based on strong financial metrics, growth potential, and solid dividend yields, ensuring resilience and steady income.» Mehr auf seekingalpha.com